Clinical Overview and Recognition of anti-NMDAR Encephalitis

Autoimmune neuroinflammatory conditions represent a major diagnostic challenge, and anti-NMDAR encephalitis remains one of the most clinically significant entities encountered in modern neurology. The condition characteristically affects young women, although patients across all demographic groups can develop the disorder. Individuals typically present with a viral prodrome featuring fever, headache, and fatigue. Within days, prominent psychiatric abnormalities emerge. Patients manifest acute psychosis, behavioral aggression, severe insomnia, and affective lability. Consequently, initial consultations frequently occur within psychiatric facilities before clinicians identify an organic neurological origin.

However, rapid neurological decline quickly follows these initial psychiatric disturbances. Patients develop progressive cognitive impairment, speech disintegration, and focal impaired awareness seizures. In addition, characteristic movement disorders including orofacial dyskinesias frequently appear. These symptoms reflect autoantibody-mediated cross-linking and internalisation of NMDA receptor GluN1 subunits. Because this process severely impairs glutamatergic synaptic transmission, profound corticolimbic dysfunction occurs. Prompt diagnostic recognition remains essential. Clinicians must identify these manifestations early so that comprehensive investigations proceed without delay.

Seizure Phenotypes and Neuroimaging Manifestations

Seizures represent a major hallmark of autoimmune encephalitis, occurring in up to eighty percent of affected patients. In this illustrative presentation, the patient developed focal impaired awareness seizures accompanied by acute cognitive decline. Focal seizures frequently originate from temporal or frontal lobe structures where NMDA receptor density is exceptionally high. Moreover, these seizures often demonstrate high resistance to conventional anti-seizure medications. Clinicians must therefore avoid relying solely on anti-seizure monotherapy when treating autoimmune epilepsy.

Furthermore, neuroimaging findings frequently present complex diagnostic hurdles. Brain magnetic resonance imaging often reveals completely normal architecture or subtle, non-specific changes. In this patient, high-resolution neuroimaging demonstrated subtle hyperintensity within the right insular cortex and adjacent subcortical white matter. Because the insula regulates central autonomic and emotional processing, these imaging abnormalities correlate closely with clinical symptomatology. Nevertheless, clinicians should never exclude encephalitis based on unremarkable scans. Up to half of all confirmed cases exhibit normal initial imaging. Electroencephalography provides crucial diagnostic support by revealing focal slowing, thereby reinforcing the urgent need for definitive lumbar puncture.

Autonomic Instability: An Underappreciated Critical Warning Sign

Autonomic instability represents one of the most dangerous features of autoimmune encephalitis, yet clinicians frequently overlook its early stages. In this patient, intermittent autonomic disturbance manifested primarily as persistent sinus tachycardia. Dysautonomia arises because pathogenic autoantibodies disrupt central regulatory pathways within the hypothalamus and brainstem. Consequently, patients alternate unpredictably between sympathetic surges and parasympathetic collapse.

Beyond persistent sinus tachycardia, autonomic dysfunction produces labile blood pressure, cardiac arrhythmias, diaphoresis, and hyperpyrexia. In addition, severe central dysautonomia can induce hypoventilation, requiring immediate mechanical ventilation in the intensive care unit. Evidence indicates that patients with prominent autonomic dysfunction experience significantly higher rates of critical care admission and prolonged morbidity. Therefore, bedside teams must implement continuous hemodynamic monitoring for all suspected cases. Early recognition of persistent tachycardia warns clinicians of impending neurological deterioration. As a result, physicians can intensify supportive care and initiate immunotherapy before hemodynamic collapse develops. Proactive management ultimately prevents secondary organ injury and lowers patient mortality.

Diagnostic Testing and Screening for Underlying Neoplasms

Establishing a definitive diagnosis requires identifying pathogenic immunoglobulin G antibodies against the GluN1 subunit of NMDA receptors. Although clinicians can detect these antibodies in serum, cerebrospinal fluid testing provides markedly superior sensitivity and specificity. Concurrently, lumbar puncture reveals mild lymphocytic pleocytosis and elevated protein levels in most patients. Therefore, neurologists strongly recommend simultaneous CSF and serum testing to prevent false-negative results.

Additionally, oncological screening represents an indispensable step in every newly confirmed adult case. Ovarian teratomas trigger aberrant autoantibody production in twenty to forty percent of female patients through ectopic neural antigen expression. Consequently, physicians must arrange comprehensive pelvic ultrasonography and pelvic magnetic resonance imaging immediately. In this reported case, extensive pelvic imaging identified no underlying teratoma or neoplasm. However, because microscopic teratomas can elude initial imaging, clinical guidelines recommend periodic surveillance over a two-year interval. Clinicians must remember that idiopathic non-tumor cases require identical aggressive immunotherapy, regardless of tumor presence.

Stepwise Immunotherapy and Escalation to Rituximab

Timely therapeutic intervention fundamentally dictates the clinical outcome in autoimmune encephalitis. International practice guidelines recommend initiating first-line immunotherapy immediately after establishing a presumptive or confirmed diagnosis. Standard first-line regimens combine high-dose intravenous methylprednisolone with intravenous immunoglobulin or plasma exchange. These therapies quickly suppress systemic inflammation and neutralize circulating autoantibodies.

However, many patients fail to achieve adequate clinical improvement with first-line therapy alone. In this case, persistent cognitive impairment prompted physicians to escalate treatment to second-line therapy with rituximab. Rituximab targets CD20-positive B cells, depleting antibody-producing precursors and halting ongoing intrathecal autoantibody generation. Clinical studies demonstrate that approximately sixty percent of treatment-refractory patients achieve significant functional recovery following second-line immunotherapy. Furthermore, initiating rituximab within ten to fourteen days significantly reduces long-term relapse risk and prevents permanent neurological deficits. Thus, decisive therapeutic escalation represents the cornerstone of modern neuroimmunology management.

Neurorehabilitation, Recovery Trajectory, and Long-Term Outcomes

Recovery from autoimmune encephalitis follows a prolonged and gradual course that mirrors the reverse order of symptom emergence. Although immunotherapy arrests immune-mediated neuronal injury, synaptic receptor recovery requires months of sustained effort. In this case, the patient gradually improved through structured inpatient neurorehabilitation, eventually regaining full functional independence and successfully returning home.

Multidisciplinary neurorehabilitation plays an essential role during this restorative phase. Cognitive retraining, speech therapy, and physical rehabilitation rebuild executive functioning, working memory, and functional mobility. Moreover, clinicians must provide dedicated psychiatric follow-up, because emotional lability and executive deficits often persist after seizure remission. In addition, long-term surveillance remains vital because disease relapse occurs in up to twenty-five percent of non-tumor cases. Relapses often manifest as subtle behavioral changes or renewed focal seizures, demanding prompt clinical re-evaluation. Therefore, scheduled follow-up visits and caregiver education ensure early detection of recrudescence. With prompt medical management, early second-line escalation, and coordinated rehabilitation, most patients achieve complete functional independence.

Frequently Asked Questions

How often does anti-NMDAR encephalitis occur without an identifiable ovarian teratoma?

Although ovarian teratomas trigger up to half of all cases in young adult women, a substantial proportion occurs without any detectable neoplasm. Tumor association strongly correlates with age, biological sex, and geographic ethnicity. In children, men, and older adults, non-tumor presentations predominate significantly. Even in young females, exhaustive pelvic ultrasonography and magnetic resonance imaging can yield negative results. Clinicians must remember that absence of a tumor does not exclude autoimmune encephalitis or delay aggressive immunotherapy.

Why is rituximab preferred when patients fail first-line immunotherapy?

Rituximab specifically targets CD20-positive B lymphocytes, depleting antibody-producing precursors that drive central nervous system neuroinflammation. When first-line corticosteroids and intravenous immunoglobulins fail to halt cognitive decline or seizures, rituximab provides robust secondary immunosuppression. Multiple clinical trials and observational cohorts demonstrate that second-line rituximab substantially improves functional independence on the modified Rankin Scale. Furthermore, its targeted administration significantly shortens total hospital stay and reduces long-term disease relapses in refractory autoimmune encephalitis presentations.

How should clinicians monitor and manage autonomic instability in this disease?

Clinicians must manage severe autonomic dysfunction in an intensive care or telemetry environment with continuous hemodynamic monitoring. Sinus tachycardia, fluctuating blood pressure, central hypoventilation, and hyperthermia require immediate recognition and targeted symptomatic support. Physicians frequently administer beta-blockers or alpha-2 agonists to control sympathetic storms and stabilize heart rates. However, definitive control of dysautonomia depends on rapid immunotherapy escalation. Prompt therapeutic suppression of pathogenic autoantibodies directly relieves autonomic brainstem disruption and prevents life-threatening cardiovascular decompensation.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

Muthiah P et al. Anti-N-Methyl-D-Aspartate Receptor Encephalitis With Autonomic Instability and Focal Seizures Without Detectable Ovarian Teratoma. Cureus. 2026 Oct undefined. doi: 10.7759/cureus.118052. PMID: 42892987.

Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15(4):391-404. doi:10.1016/S1474-4422(15)00401-9.

Dalmau J, Armangué T, Planagumà J, et al. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. Lancet Neurol. 2019;18(11):1045-1057. doi:10.1016/S1474-4422(19)30244-3.